vtx3232
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 8, 2024 (NCT06556173)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
NLRP3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06771115 | Phase 2 | Jan 7, 2025 | Zomagen Biosciences, Ltd |
| NCT06556173 | Phase 2 | Aug 8, 2024 | Zomagen Biosciences, Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zomagen Biosciences, Ltd | For profit | 2 | 2 | 1 | 2024 |
1 organizations
Page 1 / 1